Summary by Moomoo AI
eFFECTOR Therapeutics, listed on the Nasdaq Capital Market under the symbol EFTR, has filed a prospectus supplement on April 4, 2024, to amend and supplement its previous prospectus dated September 9, 2022. The company has reported the sale of 640,305 shares of common stock, raising gross proceeds of approximately $8.5 million under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. The current prospectus supplement allows for the offering and sale of additional shares with an aggregate offering price of up to $6,762,420. This offering is subject to the limitations of General Instruction I.B.6 of Form S-3, which restricts the amount eFFECTOR Therapeutics may sell. The company's public float as of April 1, 2024, was valued at $69.0 million, based on a closing stock price of $16.95 per share on March 4, 2024. Over the past 12 months, eFFECTOR Therapeutics has sold $16,235,001 worth of securities. The company cautions that investing in its common stock carries a high degree of risk, as detailed in the 'Risk Factors' section of the Prospectus.